Lobbying disclosures · Lobbying report
PFE: third_quarter 2026 lobbying report
Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues
Follow PFE- Became public
- Oct 20, 2026, 5:49 PM EDT
- Event / period date
- Not stated
- Collected
- Nov 11, 2026, 11:27 PM EST
Why this is connected
Exact legal-name match: PFIZER INC (https://www.sec.gov/Archives/edgar/data/78003/).
Reported lobbying amounts
Income: $60,000.00
These are different reporting measures. They are not added together or treated as spending on one particular bill.
Source evidence
Read the source excerpt or record
{"url":"https://lda.gov/api/v1/filings/5008646a-cf67-412c-9a4e-3029e16d153f/","filing_uuid":"5008646a-cf67-412c-9a4e-3029e16d153f","filing_type":"Q3","filing_type_display":"3rd Quarter - Report","filing_year":2026,"filing_period":"third_quarter","filing_period_display":"3rd Quarter (July 1 - Sep 30)","filing_document_url":"https://lda.gov/filings/public/filing/5008646a-cf67-412c-9a4e-3029e16d153f/print/","filing_document_content_type":"text/html","income":"60000.00","expenses":null,"expenses_method":null,"expenses_method_display":null,"posted_by_name":"Beth Anne Cole","dt_posted":"2026-10-20T17:49:04-04:00","termination_date":null,"registrant_country":"United States of America","registrant_ppb_country":null,"registrant_address_1":"611 2nd Street, NE","registrant_address_2":"Suite 1","registrant_different_address":true,"registrant_city":"Washington","registrant_state":"DC","registrant_zip":"20002","registrant":{"id":401105121,"url":"https://lda.gov/api/v1/registrants/401105121/","house_registrant_id":44305,"name":"MARSHALL & POPP, LLC","description":"​Government affairs and consulting firm.","address_1":"611 2nd Street, NE","address_2":"Suite 1","address_3":null,"address_4":null,"city":"Washington","state":"DC","state_display":"District of Columbia","zip":"20002","country":"US","country_display":"United States of America","ppb_country":"US","ppb_country_display":"United States of America","contact_name":"BETH ANNE COLE","contact_telephone":"+1 202-321-1811","dt_updated":"2026-07-13T16:40:37.032909-04:00"},"client":{"id":210229,"url":"https://lda.gov/api/v1/clients/210229/","client_id":214,"name":"PFIZER, INC.","general_description":"Biopharmaceutical manufacturing.","client_government_entity":false,"client_self_select":null,"state":"DC","state_display":"District of Columbia","country":"US","country_display":"United States of America","ppb_state":"DC","ppb_state_display":"District of Columbia","ppb_country":"US","ppb_country_display":"United States of America","effective_date":"2021-05-01"},"lobbying_activities":[{"general_issue_code":"PHA","general_issue_code_display":"Pharmacy","description":"Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. H.R. 1492, to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program Issues related to vaccine development, distribution and injury compensation. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices. Issues related to the 340B program.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70852,"prefix":null,"prefix_display":null,"first_name":"HAZEN","nickname":null,"middle_name":"CLAY","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":"Policy Director, Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don Nickles","new":false},{"lobbyist":{"id":70067,"prefix":null,"prefix_display":null,"first_name":"MONICA","nickname":null,"middle_name":null,"last_name":"POPP","suffix":null,"suffix_display":null},"covered_position":"Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint","new":false}],"government_entities":[{"id":136,"name":"Centers For Medicare and Medicaid Services (CMS)"},{"id":135,"name":"Food & Drug Administration (FDA)"},{"id":34,"name":"Health & Human Services, Dept of (HHS)"},{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"CPT","general_issue_code_display":"Copyright/Patent/Trademark","description":"Issues related to intellectual property and patent reform, including: S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70852,"prefix":null,"prefix_display":null,"first_name":"HAZEN","nickname":null,"middle_name":"CLAY","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70067,"prefix":null,"prefix_display":null,"first_name":"MONICA","nickname":null,"middle_name":null,"last_name":"POPP","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TRD","general_issue_code_display":"Trade (domestic/foreign)","description":"Issues related to tariff and trade policy.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70852,"prefix":null,"prefix_display":null,"first_name":"HAZEN","nickname":null,"middle_name":"CLAY","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70067,"prefix":null,"prefix_display":null,"first_name":"MONICA","nickname":null,"middle_name":null,"last_name":"POPP","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":198,"name":"Natl Economic Council (NEC)"},{"id":1,"name":"SENATE"}]},{"general_issue_code":"TAX","general_issue_code_display":"Taxation/Internal Revenue Code","description":"Issues related to vaccine excise taxes and the Vaccine Injury Compensation Fund.","foreign_entity_issues":"","lobbyists":[{"lobbyist":{"id":70852,"prefix":null,"prefix_display":null,"first_name":"HAZEN","nickname":null,"middle_name":"CLAY","last_name":"MARSHALL","suffix":null,"suffix_display":null},"covered_position":null,"new":false},{"lobbyist":{"id":70067,"prefix":null,"prefix_display":null,"first_name":"MONICA","nickname":null,"middle_name":null,"last_name":"POPP","suffix":null,"suffix_display":null},"covered_position":null,"new":false}],"government_entities":[{"id":2,"name":"HOUSE OF REPRESENTATIVES"},{"id":1,"name":"SENATE"}]}],"conviction_disclosures":[],"foreign_entities":[],"affiliated_organizations":[]}Congressional trading in PFE
These disclosures provide context. Their presence does not establish a link between a trader and the event.
- Nov 5, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
$15K–$50K · Traded Oct 7, 2026 · disclosed Nov 5, 2026 · Spouse
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 25, 2026 · disclosed Oct 7, 2026 · Spouse
- Oct 7, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Sep 11, 2026 · disclosed Oct 7, 2026 · Dependent
- Oct 7, 2026$15K–$50K
Rep. Ro Khanna (D-CA-17)
$15K–$50K · Traded Sep 4, 2026 · disclosed Oct 7, 2026 · Spouse
- Aug 7, 2026$1K–$15K
Rep. Michael A. Rulli (R-OH-6)
$1K–$15K · Traded Nov 26, 2024 · disclosed Aug 7, 2026 · filed 619 days later
Got $3K from the company’s PAC - Jul 21, 2026$50K–$100K
Sen. Alan Armstrong (R-OK)
$50K–$100K · Traded Mar 24, 2026 · disclosed Jul 21, 2026 · filed 119 days later
Committee overlap: HELP - Jul 16, 2026$15K–$50K
Sen. Tommy Tuberville (R-AL)
$15K–$50K · Traded Jun 8, 2026 · disclosed Jul 16, 2026 · Joint
Committee overlap: HELP - May 11, 2026$1K–$15K
Rep. Ro Khanna (D-CA-17)
$1K–$15K · Traded Apr 13, 2026 · disclosed May 11, 2026 · Spouse
Original documents control. Public records can be amended, and company connections may require interpretation. Nothing here is investment advice.